News

HS-110 is Heat’s first product candidate in a series of its proprietary Immune Pan Antigen Cytotoxic Therapy ("ImPACT") based allogeneic cell lines designed to direct killer T cells

The prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center clinical trial enrolled 230 adult and pediatric patients as young as five years of age, across 31 US sites. For the

The company is focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The trial is designed to evaluate the

Currently, Xtandi is approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy. The sNDA is based on the results from the Phase III

In Switzerland, Jetrea will be launched by ThromboGenics’ partner Alcon, a division of Novartis. Jetrea is the first pharmacological treatment for VMT and was approved by the European

Senior Scientific, a division of Manhattan Scientifics, has manufactured nanoparticles primarily to support its NanoMRX cancer detection technology. Now the company is making them available for other applications.

The team at VMBD will use the tool of metabolic engineering to transfer cannabis genetic pathways in microbes representing an alternative route to produce cannabinoids at an affordable

Pharma Two B is following the US Food and Drug Administration’s (FDA) 505(b)(2) registration pathway for P2B001. The study titled A Phase 2B, 12-week multi-center, randomized, double-blind, placebo-controlled,

Each company will bring its specific expertise to the joint venture; GrowLife providing equipment manufacturing while Vape Holdings provides guidance for the process technology and concentrate formulas. Cannabis